1.14 USD
▲+0.02+1.79%
盘后 1.63 0.00%
2026-11-20
市值
$81.38M
市盈率
—
EPS
-1.73
股息率
—
52 周区间
1.11 – 3.72
成交量
1.29M
Beta
1.25
目标价
10.17
52W 低 1.1152W 高 3.72
价格走势

公司简介

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The com...